Cardiol Therapeutics (STU:CT9) Moat Score: 3/10 (As of Jul. 07, 2026)


STU:CT9 Cardiol Therapeutics Inc STU:CT9
32 GF Score
Price €0.93
! 3 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Moat Score?

Cardiol Therapeutics STU:CT9 -0.11% 32 Moat Score is 3 as of Jul. 07, 2026. GuruFocus rates STU:CT9 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Cardiol Therapeutics ranks better than 86.05% on this metric.

Cardiol Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Cardiol Therapeutics has No Moat: Cardiol Therapeutics Inc operates in the competitive pharmaceutical industry with limited market share and no significant intellectual property or cost advantages. The company lacks strong brand recognition and customer loyalty, and its innovation capabilities are not yet proven to provide a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cardiol Therapeutics might have No Moat - Very weak/transient advantages.

Cardiol Therapeutics  (STU:CT9) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cardiol Therapeutics Moat Score Related Terms

STU:CT9 vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's Moat Score falls into.


STU:CT9
32GF Score
Cardiol Therapeutics Inc STU:CT9
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Cardiol Therapeutics (STU:CT9) has a Moat Score of 3 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cardiol Therapeutics ranks #144 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Cardiol Therapeutics' Moat Score too high?
Cardiol Therapeutics' current Moat Score is 3. Based on the distribution chart, Cardiol Therapeutics ranks #144 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #144 out of 1032 companies for Moat Score. This places Cardiol Therapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cardiol Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Moat Score of 3. The current Moat Score is 3. Cardiol Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Moat Score is 3 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
32GF Score

Get the complete analysis for STU:CT9

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.93
Price